Too Few Early Breast CA Patients Given Formal Genetic Counseling

Share this content:
Too Few Early Breast CA Patients Given Formal Genetic Counseling
Too Few Early Breast CA Patients Given Formal Genetic Counseling

WEDNESDAY, March 14, 2018 (HealthDay News) -- Many women with early-stage breast cancer with indications for formal genetic risk evaluation do not receive formal counseling, according to a study published online March 12 in the Journal of Clinical Oncology.

Steven J. Katz, M.D., M.P.H., from the University of Michigan Health Systems in Ann Arbor, and colleagues surveyed 5,080 patients aged 20 to 79 years diagnosed from July 2013 to August 2015 with early-stage breast cancer. Data were included for 1,711 patients with indications for formal genetic risk evaluation.

The researchers found that 47.4 percent of participants did not get tested, while 40.7, 7.4, and 4.5 percent tested negative, had a variant of uncertain significance, and had a pathogenic mutation, respectively. Overall, 74.6 percent received some form of genetic counseling (43.5 and 31.1 percent received formal counseling and physician-directed discussion, respectively). Almost all tested patients (96.1 percent) received some form of genetic discussion; only 50.6 percent of those not tested received any genetics discussion. Some form of counseling was more likely to be reported by younger women, with odds ratios of 4.5, 1.9, and 1.5, respectively, for women aged younger than 50 years, 50 to 59 years, and 60 to 69 years versus those aged ≥70 years, after adjustment for other factors.

"There is a large gap between mandates for timely pretest formal genetic counseling in higher-risk patients and the reality of practice today," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »